Talk:Chang Yi Wang

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

External links modified[edit]

Hello fellow Wikipedians,

I have just modified 2 external links on Chang Yi Wang. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:

When you have finished reviewing my changes, please set the checked parameter below to true or failed to let others know (documentation at {{Sourcecheck}}).

This message was posted before February 2018. After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than regular verification using the archive tool instructions below. Editors have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the RfC before doing mass systematic removals. This message is updated dynamically through the template {{source check}} (last update: 18 January 2022).

  • If you have discovered URLs which were erroneously considered dead by the bot, you can report them with this tool.
  • If you found an error with any archives or the URLs themselves, you can fix them with this tool.

Cheers.—InternetArchiveBot (Report bug) 11:04, 19 November 2016 (UTC)[reply]

External links modified[edit]

Hello fellow Wikipedians,

I have just modified 4 external links on Chang Yi Wang. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:

When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.

This message was posted before February 2018. After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than regular verification using the archive tool instructions below. Editors have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the RfC before doing mass systematic removals. This message is updated dynamically through the template {{source check}} (last update: 18 January 2022).

  • If you have discovered URLs which were erroneously considered dead by the bot, you can report them with this tool.
  • If you found an error with any archives or the URLs themselves, you can fix them with this tool.

Cheers.—InternetArchiveBot (Report bug) 19:34, 2 August 2017 (UTC)[reply]

Commons files used on this page have been nominated for deletion[edit]

The following Wikimedia Commons files used on this page have been nominated for deletion:

Participate in the deletion discussion at the nomination page. —Community Tech bot (talk) 12:06, 18 April 2019 (UTC)[reply]

Edit Request (Adding)[edit]

Dr. Wang is the author of more than 120 peer-reviewed scientific publications and she is the inventor of more than 80 patents to date[1].

In 2007, the New York Intellectual Property Law Association (NYIPLA) presented Wang with the Inventor of the Year Award[2][3][4].

In 2018, the Brain Mapping Foundation presented Dr. Wang with the Pioneer in Technology Award[5][6].

Early Life and Education

Dr. Wang graduated with honor from National Taiwan University in 1973, majoring in chemistry. She received a Ph.D. degree from Rockefeller University with dual specialization in Biochemistry and Immunology in 1979 and then joined the Memorial Sloan Kettering Cancer Center as the youngest faculty member, principal investigator and head of the molecular immunology laboratory[7].

References

  1. ^ "Publication". www.unitedbiomedical.com. Publication. Retrieved 2019-10-07.
  2. ^ "United Biomedical, Inc. CEO Dr. Chang Yi Wang named Inventor of the Year 2007 by New York Intellectual Property Law Association". NewsRx. June 17, 2007. Archived from the original on September 28, 2011. Retrieved August 5, 2011.
  3. ^ "INVENTOR OF THE YEAR - NYIPLA". www.nyipla.org/nyipla/default.asp. Retrieved 2019-10-11.
  4. ^ "New_York_Intellectual_Property_Law_Association". en.wikipedia.org. Retrieved 2019-10-11.
  5. ^ "Pioneer in Technology Award". www.worldbrainmapping.org. Retrieved 2019-10-07.
  6. ^ "Brain_Mapping_Foundation". en.wikipedia.org. Retrieved 2019-10-07.
  7. ^ "A vaccine for Alzheimer's is on the verge of becoming a reality". www.wired.co.uk. Retrieved 2019-10-11.

Reply 12-OCT-2019[edit]

  Clarification requested  

  1. Many of the claims in the Early life and education section are not referenced. Please ensure that each major claim in the article contains a reference, per WP:INTEGRITY.
  2. The hsmrt.com source contains information which was collated by the Chinese Business Committee and the Huashang Hall of Fame Service, who in turn ostensibly obtained the information from the subject herself. Please provide sources from independent, reliable WP:SECONDARY sources to confirm this information. Claims regarding degrees should originate from the bestowing university. Claims involving employment may come from the subject herself, but claims involving what title they carry or department they work in would be better serviced by being referenced by whomever the employer is.
  3. The biotaiwan.org source appears to originate from the Biotaiwan Foundation. The origins of this source's information are not entirely clear. More information needs to be provided about this source. Is it an agency which represents the Taiwanese biologics industry? Please advise.
  4. With regards to awards — By their very nature awards can be subjective, in that they represent a very specific point of view: that of the individual or organization which determines who wins the award and why. To counter this, a good practice is to limit the listing of awards to only those which are independently notable in Wikipedia.[a] To include a list of awards here, please ensure that only awards which are independently notable in Wikipedia are listed in the request.[b]
  5. Claims involving patents should be sourced using the {{cite patent}} template.
  • When ready to proceed with the requested information, kindly change the {{request edit}} template's answer parameter to read from |ans=yes to |ans=no. Thank you!

Regards,  Spintendo  11:49, 12 October 2019 (UTC)[reply]

Notes

  1. ^ An award which is independently notable is recognized by having its own article in Wikipedia.
  2. ^ What the reviewer is asking for here is not due to WP:N (which is not a content requirement). The request for notability in this case is to ensure WP:NPOV. The adding of several points of view to an article in the form of an awards section may skew the article's balance.[1] Thus, this reviewer's own practice is to limit the listing of awards to those which are independently notable in Wikipedia.

References

  1. ^ "WP:BALANCE". Wikipedia. 20 July 2019. ...articles should not give minority views or aspects as much of or as detailed a description as more widely held views or widely supported aspects.
@Spintendo: Thank you for your advice!

1. I modified my request adding content to only those easily been confirmed sourced.
2. BioTaiwan interview indicate her education background and her role in Memorial Sloan Kettering Cancer Center, but I can't get information from the employer. Can waive Early life and education content for now if you still advise lacking sufficient resource.
3. About patent, I don't list the details here, so just referring to United Biomedical website publication information page.
4. Biotaiwan Foundation's official name is "Biotechnology Industry Study Centre", an important organization of Taiwanese biologics industry.

Cmhu (talk) 16:07, 12 October 2019 (UTC)[reply]

A note about inserting text into other's comments, that is frowned upon. It's best if the comments that you leave are placed only in your reply posts. Thank you! With regards to the awards, the NYIPLA Inventor of the Year Award and the Brain Mapping Foundation's Pioneer in Technology Award have not been Wikilinked. Please advise. Also, if you could specify whether BioTaiwan is an industry trade group, meaning, do they represent the industry? Kindly specify. Thank you again Regards,  Spintendo  16:44, 12 October 2019 (UTC)[reply]
@Spintendo: Thank you for your advice again!

1. These two awards have no independent wiki, but the organization did have wiki and mention these two awards. Are they reliable enough for citation? Please advise.
2. NYIPLA is someone else's edition, I'm just adding extra information resource. I'm ok if no further modification on that.
3. I would like to remove BioTaiwan's reference since it made the citation more complicated.
4. Do you think I'm ok to post or I need to modify request edit|ans=yes to ans=no every reply and then wait for you to post for me? Thank you!Cmhu (talk) 00:49, 13 October 2019 (UTC)Cmhu[reply]

Edit Request (Adding)[edit]

Career in immunology and entrepreneurship in the biomedical industry

Dr. Wang founded United Biomedical, Inc. (UBI), headquartered in Hauppauge, New York in 1985[1], and its group of companies in Asia : UBI Asia in 1998[2], United Biopharma in 2013[3], and UBI Pharma in 2014[4] respectively. Dr. Wang advocated “immunology as a secret weapon in medicine,” devoted decades of years in synthetic peptides technology[5]. In 2009, Bill and Melinda Gates Foundation Awarded Grand Challenges Exploration Grants to Dr. Wang, for the Synthetic Peptides to Inhibit HIV Entry program[6].

The first involved developing a synthetic peptide-based HIV 1, and later an HIV 1,2 diagnostic test for blood screening, both of which received U.S. Food and Drug Administration approval, in 1989 and 1996, respectively[7][8]. These tests were subsequently recognized by the World Health Organization (WHO) as being suitable for worldwide use[9].

Her other contributions in this area include synthetic peptide-based blood screening diagnostics for HTLV I/II[10] and the Hepatitis C virus (HCV) (publication 53), which received CE mark certification and was sold in the global market through Organon Teknika /Biomerieux since 1991[11].

— Preceding unsigned comment added by Cmhu (talk • contribs) 08:20, 15 October 2019 (UTC)[reply]

References

  1. ^ "UBI Overview". www.unitedbiomedical.com. Retrieved 2019-10-11.
  2. ^ "About UBIA". www.ubiasia.com.tw. Retrieved 2019-10-11.
  3. ^ "About United BioPharma". www.unitedbiopharma.com. Retrieved 2019-10-11.
  4. ^ "UBI Pharma Company Overview". www.ubi-pharma.com. Retrieved 2019-10-11.
  5. ^ "Chang Yi Wang – Chairperson and Chief Scientific Officer (CSO), United BioPharma, Taiwan". pharmaboardroom.com. Retrieved 2019-10-11.
  6. ^ "Global Grand Challenges". gcgh.grandchallenges.org. Retrieved 2019-10-11.
  7. ^ "Detection of antibodies to human T-lymphotropic virus type III by using a synthetic peptide of 21 amino acid residues corresponding to a highly antigenic segment of gp41 envelope protein". www.pnas.org. Retrieved 2019-10-11.
  8. ^ "International Clinical Trials of HIV Vaccines: II. Phase I Trial of an HIV-1 Synthetic Peptide Vaccine Evaluating an Accelerated Immunization Schedule in Yunnan, China" (PDF). apjai-journal.org. Retrieved 2019-10-11.
  9. ^ "Diagnostics Laboratory" (PDF). www.who.int. Retrieved 2019-10-11.
  10. ^ "Improved serodiagnosis of hepatitis C virus infection with synthetic peptide antigen from capsid protein". www.ncbi.nlm.nih.gov. Retrieved 2019-10-11.
  11. ^ "Ceo Monthly April 2017". www.ceo-review.com. Retrieved 2019-10-11.

Reply 15-OCT-2019[edit]

Some issues with the requested text:

  1. Wikipedia is not the appropriate place to describe Wang's advocacy of "immunology as a secret weapon in medicine".
  2. The claims involving the "first involved developing[a] [sic?] a synthetic peptide-based HIV 1 diagnostic test" do not state clearly who developed this test, and why information about it should be posted in Wang's article (i.e., how this development was singularly shaped by her input and/or leadership should be described, along with references from reliable, WP:SECONDARY sources independent of the subject herself).
  3. The claims involving the HTLV-I/II and Hep-C virus would be more appropriately placed in an Organon Teknika / Biomerieux (OTB) article. Currently, the proposal states that the subject made "contributions" to this work while stating that OTB were the ones who marketed and sold it. This should be clarified whether the subject's contributions were made in unison with OTB or not (e.g., "Her other contributions in this area include work performed with Organon Teknika /Biomerieux in the development of synthetic peptide-based blood screening diagnostics for HTLV I/II and the Hepatitis C virus").
  4. The subject should not be referred to in the article as "Dr. Wang", per MOS:DOCTOR.
  5. The claim regarding the Gates donation does not specify whether the grant was given to the subject directly, or to a business/research group headed by her. Please clarify.
  • When ready to proceed with the requested information, kindly change the {{request edit}} template's answer parameter to read from |ans=yes to |ans=no. Also, (Please remember to sign your posts on talk pages by typing four keyboard tildes like this: ~~~~. Or, you can use the [ reply ] button, which automatically signs posts.) Thank you!

Regards,  Spintendo  13:31, 15 October 2019 (UTC)[reply]

Notes

  1. ^ The term "developing" implies that this development is ongoing.

Edit request[edit]

Career in immunology and entrepreneurship in the biomedical industry

Dr. Wang founded United Biomedical, Inc. (UBI), headquartered in Hauppauge, New York in 1985[1], and its group of companies in Asia : UBI Asia in 1998[2], United Biopharma in 2013[3], and UBI Pharma in 2014[4] respectively.

Chang Yi Wang devoted decades of years in synthetic peptides technology[5]. In 2009, Bill and Melinda Gates Foundation Awarded Grand Challenges Exploration Grants to Dr. Wang, for the Synthetic Peptides to Inhibit HIV Entry program[6].

References

  1. ^ "UBI Overview". www.unitedbiomedical.com. Retrieved 2019-10-11.
  2. ^ "About UBIA". www.ubiasia.com.tw. Retrieved 2019-10-11.
  3. ^ "About United BioPharma". www.unitedbiopharma.com. Retrieved 2019-10-11.
  4. ^ "UBI Pharma Company Overview". www.ubi-pharma.com. Retrieved 2019-10-11.
  5. ^ "Chang Yi Wang – Chairperson and Chief Scientific Officer (CSO), United BioPharma, Taiwan". pharmaboardroom.com. Retrieved 2019-10-11.
  6. ^ "Global Grand Challenges". gcgh.grandchallenges.org. Retrieved 2019-10-11.

1. Removed some complicated sentences for now.
2. https://gcgh.grandchallenges.org/grant/synthetic-peptides-inhibit-hiv-entry : Chang Yi Wang of ..., the source of Bill and Melinda Gates Foundation sentence.

@Spintendo: Thank you very much! Cmhu (talk) 06:54, 7 November 2019 (UTC) Cmhu[reply]
 Not done The requested prose is (a) already included in the article (i.e., the mentioning of the subject as the founder of UBI); (b) refers to the subject as "Dr. Wang" (per MOS:DOCTOR); (c) is not grammatical in certain areas (e.g., ...devoted decades of years...); and (d) not referenced by reliable independent WP:SECONDARY sources (i.e., her research into synthetic peptides). Additionally, (e) the claim regarding the 'Grand Challenges' grant was not added, because information found in the Bill & Melinda Gates Foundation article only references that grant as being complimentary to the Foundation's Reinvent the Toilet campaign. For these reasons the edit request is declined. Regards,  Spintendo  09:29, 7 November 2019 (UTC)[reply]
Career in immunology and entrepreneurship in the biomedical industry

Chang Yi Wang also founded UBI Asia subsidiary companies in Asia : United Biopharma in 2013[1] and UBI Pharma in 2014[2] respectively.

In 2009, Bill and Melinda Gates Foundation Awarded Grand Challenges Exploration Grants to Chang Yi Wang, for the Synthetic Peptides to Inhibit HIV Entry program[3].

References

  1. ^ "About United BioPharma". www.unitedbiopharma.com. Retrieved 2019-10-11.
  2. ^ "UBI Pharma Company Overview". www.ubi-pharma.com. Retrieved 2019-10-11.
  3. ^ "Global Grand Challenges". gcgh.grandchallenges.org. Retrieved 2019-10-11.
@Spintendo: Thanks for your promptly reply and advice.

1. Removed duplicate information.
2. Modified content.
3. "Chang Yi Wang of United Biomedical, Inc. in the United States will develop and test synthetic peptide immunogens that mimic conserved sites used by HIV to gain entry to host T-cells. Mimicking the correct three-dimensional structure of these important proteins should generate antibody responses that block this initial step of HIV infection and neutralize the virus." From Bill and Melinda Gates Foundation official website Awarded Grants webpage, isn't it a clear and reliable resource? Cmhu (talk) 10:37, 7 November 2019 (UTC)[reply]

Retrieved from "https://en.wikipedia.org/w/index.php?title=Talk:Chang_Yi_Wang&oldid=1206617906"